What the research found

Researchers measured thyroid function in 244 Kenyan children and young adults with Type 1 diabetes, using TSH and free thyroxine (FT4) to classify thyroid status. About three-quarters had normal thyroid function, while roughly one in nine showed biochemically defined thyroid dysfunction. The majority of cases were hypothyroidism—mostly in its subclinical form (elevated TSH but normal FT4), with a smaller proportion showing overt hypothyroidism (both TSH and FT4 abnormal). A notable additional finding was that over 11% had discordant TSH-FT4 patterns that didn't fit standard diagnostic categories, suggesting thyroid function can present in ways that complicate straightforward interpretation.

Interestingly, demographic factors like age, sex, and how long someone had lived with diabetes didn't predict who developed thyroid dysfunction in this population. This differs from some patterns observed in higher-income countries and hints that thyroid comorbidity in T1D may have different drivers depending on geographic or population context.

Why it matters for you

If you have Type 1 diabetes and track biomarkers via MyKine, this underscores why routine TSH and FT4 measurement deserves a place in your protocol—even if you feel well. Subclinical hypothyroidism (the most common form here) produces no obvious symptoms but can affect metabolism, energy, body composition, and how your immune system behaves, all of which interact with glucose control and recovery from training.

The finding that discordant TSH-FT4 patterns are common is practical: if your TSH looks borderline or slightly off but FT4 appears normal, that's worth interpreting carefully rather than dismissing. It's also a reminder that single-test snapshots can be misleading—regular tracking and trend analysis give you more reliable signal than one-off measurements.

For T1D users specifically, thyroid screening should be part of baseline assessment and periodic review (the authors suggest this is underutilized in some settings), since thyroid dysfunction compounds the metabolic load already present with diabetes management.

Caveats

  • Cross-sectional design: shows prevalence at a moment in time, not causation or how dysfunction develops
  • Limited to Kenya; patterns may differ in other populations
  • Age range extended to 34 years, mixing children and adults—subgroup patterns not separately reported
  • No information on whether participants were on diabetes medications, insulin regimens, or other treatments that might influence thyroid status
  • No clinical outcomes reported; unclear whether subclinical cases require intervention